Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during the 2022 to 2023 season.

LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial Virus ...

During the COVID pandemic, RSV showed a slightly odd pattern: like flu, it basically disappeared in the 2020–2021 season, ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

US health officials have issued a warning linking RSV vaccines to an increased risk of a serious neurological condition. The ...

The Cyprus pulmonology society on Thursday urged Health Minister Michael Damianos to approve a respiratory syncytial virus ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

“RSV isn’t reportable, but surveillance shows an uptick in cases. Fortunately, we now have vaccines for older adults and antibody treatments for babies,” Meyerson said. Meyerson ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased risk for Guillain-Barré Syndrome (GBS) within 42 days of vaccination ...